Search Blog
Categories
November 2013
M T W T F S S
« Oct   Dec »
 123
45678910
11121314151617
18192021222324
252627282930  

Tags

FSLR, WDC, ARNA and DRAD added to NASDAQ Active Stock Watch List at EPR

admin

By Equity Profile Report

New York, NY – (ACCESSWIRE) – 11/01/2013 – Equity Profile Report initiates its NASDAQ Active Stock Weekly Watch List adding First Solar, Inc. (NASDAQ:FSLR), Western Digital Corporation (NASDAQ:WDC), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), and Digirad Corporation (NASDAQ:DRAD)

First Solar, Inc. (NASDAQ:FSLR) provides solar energy solutions is currently up (+15.06%) on 7,566,742 shares traded after FIRST SOLAR, INC. Filed SEC form 10-Q, Quarterly Report. First Solar, Inc. (NASDAQ:FSLR) is currently up (+156.44%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about First Solar, Inc. (NASDAQ:FSLR)  

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=FSLR&SubId=AW

Western Digital Corporation (NASDAQ:WDC) a company that through its subsidiaries, develops, manufactures, and sells storage products and solutions that enable people to create, manage, experience, and preserve digital content is currently down (-0.19%) on 3,080,638 shares traded after WESTERN DIGITAL CORP Filed SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits. Western Digital Corporation (NASDAQ:WDC) is currently down (-7.67%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Western Digital Corporation (NASDAQ:WDC)  

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=WDC&SubId=AW

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) a biopharmaceutical company that engages in discovering, developing, and commercializing novel drugs that target G protein-coupled receptors in the therapeutic areas of cardiovascular, central nervous system, inflammatory, and metabolic diseases is currently down (-3.54%) on 2,473,668 shares traded after Arena Pharmaceuticals announced to Host Corporate Update and Financial Results Conference Call and Webcast on Thursday, November 7. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is currently down (-62.36%) from its recent 52-week high, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)  

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=ARNA&SubId=AW

Digirad Corporation (NASDAQ:DRAD) a company that provides diagnostic solutions in the science of imaging primarily in the United States is currently up (+18.62%) on 538,107 shares traded after Digirad Corporation Reported Third Quarter and Nine-Month Financial Results. Digirad Corporation (NASDAQ:DRAD) is currently up (+132.77%) from its recent 52-week low, which has prompted Equity Profile Report to add the stock to their NASDAQ Active Stock Watch List and Investor Poll.

To find out what other Investors are saying about Digirad Corporation (NASDAQ:DRAD)

Click Here: http://www.equityprofilereport.com/Survey.aspx?stock=DRAD&SubId=AW 

Equityprofilereport.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Equityprofilereport.com is often aware of several large investor awareness campaigns being deployed. Timing is important when trading Small Caps and Penny Stocks.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.Equityprofilereport.com 

Disclosure: Equityprofilereport.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Equityprofilereport.com website, for complete risks and disclosures. 

Contact Info:
Equity Profile Report
editor@Equityprofilereport.com